Spots Global Cancer Trial Database for A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Official Title: A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Study ID: NCT05581004
Study Description
Brief Summary: This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University', San Francisco, California, United States
University Of Colorado, Aurora, Colorado, United States
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
Winship Cancer Institute, Atlanta, Georgia, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Hospital, Detroit, Michigan, United States
Washington University Medical Center, Division of Oncology, Saint Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
The West Clinic - Memphis (Union Ave), Germantown, Tennessee, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia
Monash Health Monash Medical Centre, Clayton, Victoria, Australia
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
UZ Antwerpen, Edegem, , Belgium
CHU de Liège, Liège, , Belgium
GasthuisZusters Antwerpen, Wilrijk, , Belgium
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
Seoul National University Hospital, Seoul, , Korea, Republic of
Asan Medical Center - PPDS, Seoul, , Korea, Republic of
Samsung Medical Center - PPDS, Seoul, , Korea, Republic of
Severance Hospital Yonsei University Health System - Clinical Trials Center Pharmacy, Seoul, , Korea, Republic of
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, , Netherlands
Universitair Medisch Centrum Groningen, Groningen, , Netherlands
ICO l?Hospitalet ? Hospital Duran i Reynals, L?Hospitalet De Llobregat, Barcelona, Spain
Hospital Universitario Vall d'Hebron - PPDS, Barcelona, , Spain
START MADRID_Hospital Universiario Fundacion Jimenez Diaz, Madrid, , Spain
Hospital Universitario 12 De Octubre, Madrid, , Spain
Hospital Universitario Virgen de la Victoria, Malaga, , Spain
Hospital Clinico Universitario de Valencia, Valencia, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
